Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
journalStr:"WHO International Clinical Trials Registry Platform"
topic_facet:"Phase: Phase 4"
topic_facet:"Medical Condition: ASTHMA UNCONTROLLED ON MEDIUM DOSES OF INHALED CORTICOSTEROIDS IN COMBINATION WITH LONG-ACTING ß2- AGONISTS MedDRA version: 22.1Level: LLTClassification code 10003555Term: Asthma bronchialSystem Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22&filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+4%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+ASTHMA+UNCONTROLLED+ON+MEDIUM+DOSES+OF+INHALED+CORTICOSTEROIDS+IN+COMBINATION+WITH+LONG-ACTING+%C3%9F2-+AGONISTS+MedDRA+version%3A+22.1Level%3A+LLTClassification+code+10003555Term%3A+Asthma+bronchialSystem+Organ+Class%3A+100000004855%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Respiratory+Tract+Diseases+%5BC08%5D%22&lookfor=Dexamethasone+OR+corticosteroid&type=AllFields
/vufind/Search/Results?filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22&filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+4%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+ASTHMA+UNCONTROLLED+ON+MEDIUM+DOSES+OF+INHALED+CORTICOSTEROIDS+IN+COMBINATION+WITH+LONG-ACTING+%C3%9F2-+AGONISTS+MedDRA+version%3A+22.1Level%3A+LLTClassification+code+10003555Term%3A+Asthma+bronchialSystem+Organ+Class%3A+100000004855%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Respiratory+Tract+Diseases+%5BC08%5D%22&lookfor=Dexamethasone+OR+corticosteroid&type=AllFields
Search /vufind/Search2/Results?filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22&filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+4%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+ASTHMA+UNCONTROLLED+ON+MEDIUM+DOSES+OF+INHALED+CORTICOSTEROIDS+IN+COMBINATION+WITH+LONG-ACTING+%C3%9F2-+AGONISTS+MedDRA+version%3A+22.1Level%3A+LLTClassification+code+10003555Term%3A+Asthma+bronchialSystem+Organ+Class%3A+100000004855%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Respiratory+Tract+Diseases+%5BC08%5D%22&lookfor=Dexamethasone+OR+corticosteroid&type=AllFields
PubPharm (22)
1
A clinical trial comparing of 4 doses of CHF 5993 100/6/12.5 µg pMDI to 4 doses of CHF 1535 200/6 µg pMDI in subjects with asthma. : A 26 WEEK, RANDOMIZED, DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, ACTIVE CONTROLLED, 2-ARM PARALLEL GROUP TRIAL COMPARING CHF 5993 100/6/12.5 µg pMDI (FIXED COMBINATION OF EXTRAFINE FORMULATION OF BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE PLUS GLYCOPYRRONIUM BROMIDE) TO CHF 1535 200/6 µg pMDI (FIXED COMBINATION OF EXTRAFINE FORMULATION OF BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE) IN SUBJECTS WITH ASTHMA UNCONTROLLED ON MEDIUM DOSES OF INHALED CORTICOSTEROIDS IN COMBINATION WITH LONG-ACTING ß2-AGONISTS. - MiSTIC
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
2
A clinical trial comparing of 4 doses of CHF 5993 100/6/12.5 µg pMDI to 4 doses of CHF 1535 200/6 µg pMDI in subjects with asthma. : A 26 WEEK, RANDOMIZED, DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, ACTIVE CONTROLLED, 2-ARM PARALLEL GROUP TRIAL COMPARING CHF 5993 100/6/12.5 µg pMDI (FIXED COMBINATION OF EXTRAFINE FORMULATION OF BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE PLUS GLYCOPYRRONIUM BROMIDE) TO CHF 1535 200/6 µg pMDI (FIXED COMBINATION OF EXTRAFINE FORMULATION OF BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE) IN SUBJECTS WITH ASTHMA UNCONTROLLED ON MEDIUM DOSES OF INHALED CORTICOSTEROIDS IN COMBINATION WITH LONG-ACTING ß2-AGONISTS. - MiSTIC
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
3
A clinical trial comparing of 4 doses of CHF 5993 100/6/12.5 µg pMDI to 4 doses of CHF 1535 200/6 µg pMDI in subjects with asthma. : A 26 WEEK, RANDOMIZED, DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, ACTIVE CONTROLLED, 2-ARM PARALLEL GROUP TRIAL COMPARING CHF 5993 100/6/12.5 µg pMDI (FIXED COMBINATION OF EXTRAFINE FORMULATION OF BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE PLUS GLYCOPYRRONIUM BROMIDE) TO CHF 1535 200/6 µg pMDI (FIXED COMBINATION OF EXTRAFINE FORMULATION OF BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE) IN SUBJECTS WITH ASTHMA UNCONTROLLED ON MEDIUM DOSES OF INHALED CORTICOSTEROIDS IN COMBINATION WITH LONG-ACTING ß2-AGONISTS. - MiSTIC
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
4
A clinical trial comparing of 4 doses of CHF 5993 100/6/12.5 µg pMDI to 4 doses of CHF 1535 200/6 µg pMDI in subjects with asthma. : A 26 WEEK, RANDOMIZED, DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, ACTIVE CONTROLLED, 2-ARM PARALLEL GROUP TRIAL COMPARING CHF 5993 100/6/12.5 µg pMDI (FIXED COMBINATION OF EXTRAFINE FORMULATION OF BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE PLUS GLYCOPYRRONIUM BROMIDE) TO CHF 1535 200/6 µg pMDI (FIXED COMBINATION OF EXTRAFINE FORMULATION OF BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE) IN SUBJECTS WITH ASTHMA UNCONTROLLED ON MEDIUM DOSES OF INHALED CORTICOSTEROIDS IN COMBINATION WITH LONG-ACTING ß2-AGONISTS. - MiSTIC
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
5
A clinical trial comparing of 4 doses of CHF 5993 100/6/12.5 µg pMDI to 4 doses of CHF 1535 200/6 µg pMDI in subjects with asthma. : A 26 WEEK, RANDOMIZED, DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, ACTIVE CONTROLLED, 2-ARM PARALLEL GROUP TRIAL COMPARING CHF 5993 100/6/12.5 µg pMDI (FIXED COMBINATION OF EXTRAFINE FORMULATION OF BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE PLUS GLYCOPYRRONIUM BROMIDE) TO CHF 1535 200/6 µg pMDI (FIXED COMBINATION OF EXTRAFINE FORMULATION OF BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE) IN SUBJECTS WITH ASTHMA UNCONTROLLED ON MEDIUM DOSES OF INHALED CORTICOSTEROIDS IN COMBINATION WITH LONG-ACTING ß2-AGONISTS. - MiSTIC
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
6
A clinical trial comparing of 4 doses of CHF 5993 100/6/12.5 µg pMDI to 4 doses of CHF 1535 200/6 µg pMDI in subjects with asthma. : A 26 WEEK, RANDOMIZED, DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, ACTIVE CONTROLLED, 2-ARM PARALLEL GROUP TRIAL COMPARING CHF 5993 100/6/12.5 µg pMDI (FIXED COMBINATION OF EXTRAFINE FORMULATION OF BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE PLUS GLYCOPYRRONIUM BROMIDE) TO CHF 1535 200/6 µg pMDI (FIXED COMBINATION OF EXTRAFINE FORMULATION OF BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE) IN SUBJECTS WITH ASTHMA UNCONTROLLED ON MEDIUM DOSES OF INHALED CORTICOSTEROIDS IN COMBINATION WITH LONG-ACTING ß2-AGONISTS. - MiSTIC
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
7
A clinical trial comparing of 4 doses of CHF 5993 100/6/12.5 µg pMDI to 4 doses of CHF 1535 200/6 µg pMDI in subjects with asthma. : A 26 WEEK, RANDOMIZED, DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, ACTIVE CONTROLLED, 2-ARM PARALLEL GROUP TRIAL COMPARING CHF 5993 100/6/12.5 µg pMDI (FIXED COMBINATION OF EXTRAFINE FORMULATION OF BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE PLUS GLYCOPYRRONIUM BROMIDE) TO CHF 1535 200/6 µg pMDI (FIXED COMBINATION OF EXTRAFINE FORMULATION OF BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE) IN SUBJECTS WITH ASTHMA UNCONTROLLED ON MEDIUM DOSES OF INHALED CORTICOSTEROIDS IN COMBINATION WITH LONG-ACTING ß2-AGONISTS. - MiSTIC
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
8
A clinical trial comparing of 4 doses of CHF 5993 100/6/12.5 µg pMDI to 4 doses of CHF 1535 200/6 µg pMDI in subjects with asthma. : A 26 WEEK, RANDOMIZED, DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, ACTIVE CONTROLLED, 2-ARM PARALLEL GROUP TRIAL COMPARING CHF 5993 100/6/12.5 µg pMDI (FIXED COMBINATION OF EXTRAFINE FORMULATION OF BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE PLUS GLYCOPYRRONIUM BROMIDE) TO CHF 1535 200/6 µg pMDI (FIXED COMBINATION OF EXTRAFINE FORMULATION OF BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE) IN SUBJECTS WITH ASTHMA UNCONTROLLED ON MEDIUM DOSES OF INHALED CORTICOSTEROIDS IN COMBINATION WITH LONG-ACTING ß2-AGONISTS. - MiSTIC
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
9
A clinical trial comparing of 4 doses of CHF 5993 100/6/12.5 µg pMDI to 4 doses of CHF 1535 200/6 µg pMDI in subjects with asthma. : A 26 WEEK, RANDOMIZED, DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, ACTIVE CONTROLLED, 2-ARM PARALLEL GROUP TRIAL COMPARING CHF 5993 100/6/12.5 µg pMDI (FIXED COMBINATION OF EXTRAFINE FORMULATION OF BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE PLUS GLYCOPYRRONIUM BROMIDE) TO CHF 1535 200/6 µg pMDI (FIXED COMBINATION OF EXTRAFINE FORMULATION OF BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE) IN SUBJECTS WITH ASTHMA UNCONTROLLED ON MEDIUM DOSES OF INHALED CORTICOSTEROIDS IN COMBINATION WITH LONG-ACTING ß2-AGONISTS (MiSTIC). - MiSTIC
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
10
A clinical trial comparing of 4 doses of CHF 5993 100/6/12.5 µg pMDI to 4 doses of CHF 1535 200/6 µg pMDI in subjects with asthma. : A 26 WEEK, RANDOMIZED, DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, ACTIVE CONTROLLED, 2-ARM PARALLEL GROUP TRIAL COMPARING CHF 5993 100/6/12.5 µg pMDI (FIXED COMBINATION OF EXTRAFINE FORMULATION OF BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE PLUS GLYCOPYRRONIUM BROMIDE) TO CHF 1535 200/6 µg pMDI (FIXED COMBINATION OF EXTRAFINE FORMULATION OF BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE) IN SUBJECTS WITH ASTHMA UNCONTROLLED ON MEDIUM DOSES OF INHALED CORTICOSTEROIDS IN COMBINATION WITH LONG-ACTING ß2-AGONISTS. - MiSTIC
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
1
2
3
Nächster »
[3]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Zeitschrift: WHO International Clinical Trials Registry Platform
Filter aufheben
Thema: Phase: Phase 4
Filter aufheben
Thema: Medical Condition: ASTHMA UNCONTROLLED ON MEDIUM DOSES OF INHALED CORTICOSTEROIDS IN COMBINATION WITH LONG-ACTING ß2- AGONISTS MedDRA version: 22.1Level: LLTClassification code 10003555Term: Asthma bronchialSystem Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Medienart
22
Aufsätze
22
E-Artikel
22
E-Ressourcen
Zeitschriftentitel
WHO International Clinical Trials Registry Plat...
Thema
22
610
Medical Condition: ASTHMA UNCONTROLLED ON MEDIU...
Phase: Phase 4
22
Recruitment Status: Authorised-recruitment may ...
22
Study Type: Interventional
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
4
2023
16
2022
2
2021
Erscheinungsjahr(e)
Von:
Bis:
Sprache
22
Englisch
Haven't found what you're looking for?
Wird geladen...